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Abstract. Gliomas are the most common primary brain malignancies, with different degrees of aggressiveness, vari-
able prognosis and various heterogeneous histologic sub-regions, i.e., peritumoral edematous/invaded tissue, necrotic
core, active and non-enhancing core. This intrinsic heterogeneity is also portrayed in their radio-phenotype, as their
sub-regions are depicted by varying intensity profiles disseminated across multi-parametric magnetic resonance imag-
ing (mpMRI) scans, reflecting varying biological properties. Their heterogeneous shape, extent, and location are some
of the factors that make these tumors difficult to resect, and in some cases inoperable. The amount of resected tumor
is a factor also considered in longitudinal scans, when evaluating the apparent tumor for potential diagnosis of pro-
gression. Furthermore, there is mounting evidence that accurate segmentation of the various tumor sub-regions can
offer the basis for quantitative image analysis towards prediction of patient overall survival. This study assesses the
state-of-the-art machine learning (ML) methods used for brain tumor image analysis in mpMRI scans, during the last
seven instances of the International Brain Tumor Segmentation (BraTS) challenge, i.e., 2012-2018. Specifically, we
focus on i) evaluating segmentations of the various glioma sub-regions in pre-operative mpMRI scans, ii) assessing
potential tumor progression by virtue of longitudinal growth of tumor sub-regions, beyond use of the RECIST/RANO
criteria, and iii) predicting the overall survival from pre-operative mpMRI scans of patients that underwent gross total
resection. Finally, we investigate the challenge of identifying the best ML algorithms for each of these tasks, consider-
ing that apart from being diverse on each instance of the challenge, the multi-institutional mpMRI BraTS dataset has
also been a continuously evolving/growing dataset.
Keywords: BraTS, challenge, brain, tumor, segmentation, machine learning, glioma, glioblas-
toma, radiomics, survival, progression, RECIST, RANO
1 Introduction
1.1 Scope
The Brain Tumor segmentation (BraTS) challenge focuses on the evaluation of state-of-the-art
methods for the segmentation of brain tumors in multi-parametric magnetic resonance imaging
(mpMRI) scans. Its primary role since its inception has been two-fold: a) a publicly available dataset
and b) a community benchmark [1–4]. BraTS utilizes multi-institutional pre-operative mpMRI scans
and focuses on the segmentation of intrinsically heterogeneous (in appearance, shape, and histol-
ogy) brain tumors, namely gliomas. Furthermore, to pinpoint the clinical relevance of this segmen-
tation task, BraTS 2018 also focuses on the prediction of patient overall survival, via integrative
analyses of radiomic features and machine learning (ML) algorithms.
1.2 Clinical Relevance
Gliomas are the most common primary brain malignancies, with different degrees of aggressive-
ness, variable prognosis and various heterogeneous histological sub-regions, i.e., peritumoral ede-
matous/invaded tissue, necrotic core, active and non-enhancing core. This intrinsic heterogeneity
of gliomas is also portrayed in their imaging phenotype (appearance and shape), as their sub-
regions are described by varying intensity profiles disseminated across mpMRI scans, reflecting
varying tumor biological properties. Due to this highly heterogeneous appearance and shape, seg-
mentation of brain tumors in multimodal MRI scans is one of the most challenging tasks in medical
image analysis.
Fig. 1: Search on PubMed in 2012 showing related growing body of literature. Figure taken from
[1].
1.3 Before the BraTS era
There has been a growing body of literature on computational algorithms addressing this important
task (Fig. 1). Unfortunately, open manually-annotated datasets for designing and testing these
algorithms are not currently available, and private datasets differ so widely that it is hard to compare
the different segmentation strategies that have been reported so far. Critical factors leading to
these differences include, but are not limited to, i) the imaging modalities employed, ii) the type of
the tumor (glioblastoma or lower grade glioma, primary or secondary tumors, solid or infiltratively
growing), and iii) the state of disease (images may not only be acquired prior to treatment, but
also post-operatively and therefore show radiotherapy effects and surgically-imposed cavities).
Towards this end, BraTS is making available a large dataset of mpMRI [1–4], with accompanying
delineations of the relevant tumor sub-regions (Fig. 2). The exact mpMRI data consists of a) a
native T1-weighted scan (T1), b) a post-contrast T1-weighted scan (T1Gd), c) a native T2-weighted
scan (T2), and d) a T2 Fluid Attenuated Inversion Recovery (T2-FLAIR) scan.
1.4 BraTS 2017 vs 2018
The last two instances of BraTS (i.e., 2017 and 2018) were focused on both the segmentation of
tumor sub-structures, and the prediction of overall survival of patients diagnosed with primary de
novo glioblastoma (GBM).
Fig. 2: Glioma sub-regions. The image patches show from left to right: the whole tumor (yellow)
visible in T2-FLAIR (A), the tumor core (red) visible in T2 (B), the active tumor structures (light
blue) visible in T1Gd, surrounding the cystic/necrotic components of the core (green) (C). The
segmentations are combined to generate the final labels of the tumor sub-regions (D): ED (yellow),
NET (red), NCR cores (green), AT (blue). Figure taken from [1].
Fig. 3: Illustrative pipeline example for predicting patient overall survival.
For the segmentation of gliomas in pre-operative mpMRI scans, the participants were called
to address this task by using the provided clinically-acquired training data to develop automated
methods and produce segmentation labels of the different glioma sub-regions.
For the task of patient overall survival (OS) prediction from pre-operative mpMRI scans, once
the participants produce their segmentation labels in the pre-operative scans, they were called to
use these labels in combination with the provided mpMRI data to extract imaging/radiomic features
that they consider appropriate [5], and analyze them through ML algorithms, to predict patient OS
(Fig. 3). The participants do not need to be limited to volumetric parameters, but can also consider
intensity, morphologic, histogram-based, and textural features, as well as spatial information, and
glioma diffusion properties extracted from glioma growth models.
2 Materials and Methods
Table 1: Summarizing the original characteristics of the BraTS dataset.
Acronym MRI Sequence Property Acquisition Slice thickness
T1 T1-weighted Native image Sagittal or Axial Variable (1-5mm)
T1Gd T1-weighted post-contrast enhancement (Gadolinium) Axial 3D acquisition Variable
T2 T2-weighted Native image Axial 2D Variable (2-4mm)
T2-FLAIR T2-weighted Native image Axial or Coronal or Sagittal 2D Variable
2.1 BraTS Annotations and Structures
All the imaging datasets have been segmented manually, by one to four raters, following the same
annotation protocol, and their ground truth annotations were approved by experienced neuro-
radiologists. The tumor sub-regions considered for evaluation are: 1) the ”active tumor” (AT), 2)
the gross tumor, also known as the ”tumor core” (TC), and 3) the complete tumor extent also re-
ferred to as the ”whole tumor” (WT) (Fig. 2). The AT is described by areas that show hyper-intensity
in T1Gd when compared to T1, but also when compared to ”healthy” white matter in T1Gd. The
TC describes the bulk of the tumor, which is what is typically resected. The TC entails the AT, as
well as the necrotic (fluid-filled) and the non-enhancing (solid) parts of the tumor. The appearance
of the necrotic (NCR) and the non-enhancing (NET) tumor core is typically hypo-intense in T1-Gd
when compared to T1. The WT describes the complete extent of the disease, as it entails the TC
and the peritumoral edematous/invaded tissue (ED), which is typically depicted by hyper-intense
signal in T2-FLAIR.
The ground truth annotations were only approved by domain experts whereas they are actually
created by multiple experts. Although a very specific annotation protocol (described below) was
provided to each data contributing institution, slightly different annotation styles were noted for the
various raters involved in the process. Therefore, all final labels included in the BraTS dataset
were also further reviewed for consistency and compliance with the annotation protocol by a single
board-certified neuro-radiologist with more than 15 years of experience.
2.2 Annotation Protocol
The BraTS dataset describes a collection of brain tumor MRI scans acquired from multiple different
centers under standard clinical conditions, but with different equipment and imaging protocols,
resulting in a vastly heterogeneous image quality reflecting diverse clinical practice across different
institutions. However, we designed the following tumor annotation protocol, in order to make it
possible to create similar ground truth delineations across various annotators.
For the tasks related to BraTS, only structural MRI volumes were considered (T1, T1Gd, T2,
T2-FLAIR), all of them co-registered to a common anatomical template (SRI [6]) and resampled to
1mm3. The details of the original scans are given in Table 1. Note that different native T1 scans
exist, depending on whether they were 3D acquisitions, or 2D fast spin echo, or even just localizing
images, and therefore not all T1 scans can be considered suitable for the task of segmentation.
To our experience the T1Gd and the T2-FLAIR volumes have been the most useful to produce the
ground truth segmentations.
We note that radiologic definition of tumor boundaries, especially in such infiltrative tumors
as gliomas, is a well-known problem. In an attempt to offer a standardized approach to assess
and evaluate various tumor sub-regions, the BraTS initiative, after consultation with internationally-
recognized expert neuroradiologists, defined the following types of tumor sub-regions. However, we
note that other criteria for delineation could be set, resulting in slightly different tumor sub-regions.
The BraTS tumor sub-regions do not reflect strict biologic entities, but are rather image-based.
For instance, the definition of the AT could simply be the regions with hyper-intense signal on
T1Gd images. However, in high grade tumors, there are non-necrotic, non-cystic regions that do
not enhance, but can be separable from the surrounding vasogenic edema, and represent non-
enhancing infiltrative tumor. Another problem is the definition of tumor center in low-grade gliomas.
In such cases, it is difficult to differentiate tumor from vasogenic edema, particularly in the absence
of enhancement. It is also noteworthy that in order to produce the ground truth labels used in
the provided data, we have recommended to start delineating the sub-regions of interest from
the outside tumor boundaries, i.e., one should start from the manual delineation of the abnormal
signal in the T2-weighted images, primarily defining the WT, then address the TC, and finally the
enhancing and non-enhancing/necrotic core, possibly using semi-automatic tools.
2.2.1 BraTS 2012-2016 (Four tumor sub-regions) BraTS 2012-2016 defined four tumor sub-
regions, delineating the AT, NET, NCR, and ED.
Label 1: NCR. This sub-region describes the necrotic core, or necrocyst, that resides within the
enhancing rim of high grade gliomas, and sometimes appears cystic.
Label 2: ED. This sub-region describes the peritumoral edematous and invaded tissue that is fairly
easily defined on the T2-weighted images, as a hyperintense abnormal signal distribution, and
hypo-intense signal on T1. This label primarily describes the tentacle-like shaped regions of
edematous white matter into the subcortex of the gyri and, importantly, this is distinguished
from cystic regions and the ventricles.
Label 3: NET. It is possible to identify such regions depicting the non-enhancing gross abnormal-
ity, by viewing the T2-weighted images. Some parts of the high-grade tumor do not enhance,
but they are clearly distinguishable from the surrounding vasogenic edema on T2, as they have
lower signal intensity and heterogeneous texture. Moreover, in low grade gliomas, this is the
only category used for delineating the gross tumor.
Label 4: AT. This is a relatively easy definition, as it describes the enhancing regions within the
gross tumor abnormality, but not the necrotic center. The threshold to exclude the necrotic
center from the enhancing part should be set independently per subject. Note that vessels
running in the neighboring regions and sulci are not included.
We cautiously note that the NET (i.e., ”Label 3”) can be overestimated by some annotators, and
that oftentimes there is little evidence in the image data for this sub-region. Therefore, forcing
the definition of this region could introduce an artifact, which could result in substantially different
ground truth labels created from the annotators in different institutions. This case could potentially
have implications in the ranking of the BraTS participants, i.e., a ranking bias towards the test
cases ground truth annotator instead of ranking the actual algorithmic performance.
2.2.2 BraTS 2017-Present (Three tumor sub-regions) In order to address the aforementioned
issue, in BraTS 2017 the NET label (”Label 3”) has been eliminated and combined with NCR (”La-
bel 1”). Furthermore, contralateral and periventricular regions of T2-FLAIR hyper-intensity were
excluded from the ED region, unless they were contiguous with peritumoral ED, as these areas are
generally considered to represent chronic microvascular changes, or age-associated demyelina-
tion, rather than tumor infiltration [7]. The rationale for this is that contralateral and periventricular
white matter hyper-intensities regions might be considered pre-existing conditions, related to small
vessel ischemic disease, especially in older patients.
WT: Segmenting the whole tumor extent (Union of all labels). One should start by loading the
T2-FLAIR images and creating a new label for the WT. We recommend to start from the top of
the brain (i.e., superiorly) and since this sub-region is usually the larger with a relatively smooth
shape, it is sufficient to make manual delineations every third slice. Then morphological oper-
ations of dilation and erosion can be used to fill the in-between axial slices. Finally, smoothing
with a Gaussian kernel (σ = 1) can be used to smooth the jaggedness of the label on coronal
and sagittal views.
TC: Segmenting the gross tumor core outline (Union of labels 1, 3, and 4). For this sub-region,
it is necessary to check whether there are non-enhancing tumor regions. The TC boundaries
can be delineated on every other slice. Then, morphological operations of dilation and erosion
can be used to fill the in-between axial slices, followed by a Gaussian smoothing filter to help
with the non-continuous delineations on coronal view. Once the TC boundaries are defined, the
remaining of the WT will correspond to the ED sub-region (”Label 2”), which is described by
hyper-intense signal on the T2-FLAIR volumes.
AT: Segmenting the active and the non-enhancing/necrotic tumor regions. The active tu-
mor (AT - i.e., enhancing rim) is described by areas that show hyper-intensity on T1-Gd when
compared to T1, but also when compared to normal/healthy white matter (WM) in T1Gd. Bio-
logically, AT is felt to represent regions where there is leakage of contrast through a disrupted
blood-brain barrier that is commonly seen in high grade gliomas. The NET represents non-
enhancing tumor regions, as well as transitional/prenecrotic and necrotic regions that belong
to the non-enhancing part of the TC, and are typically resected in addition to the AT. The ap-
pearance of the NET is typically hypo-intense in T1-Gd when compared to T1, but also when
compared to normal/healthy WM in T1-Gd.
To delineate the AT in gliomas, we suggest to use the T1Gd scans and the existing TC outline.
One can then set an intensity threshold within this label to distinguish between the high intensity
active/enhancing tumor and the low intensity non-enhancing/necrotic (and very tortuous) core
regions. Note that the choroid plexus and areas of hemorrhage (when they can be identified by
comparing to the native T1 scan), should not be labeled.
LGG: Remarks on low grade gliomas. For low grade gliomas (LGGs), we note that they do not
exhibit much contrast enhancement, or ED. Biologically, LGGs may have less blood-brain bar-
rier disruption (leading to less leak of contrast during the scan), and may grow at a rate slow
enough to avoid significant edema formation, which results from rapid disruption, irritation, and
infiltration of normal brain parenchyma by tumor cells. Specifically, after taking all the above into
consideration, in scans of LGGs without an apparent ET area, we consider only the NET and
vasogenic ED labels, by observing the texture or the intensity on T2-FLAIR images, whereas
in LGG scans without ET and without obvious texture differences across modalities (e.g., small
astrocytomas) we consider only the NET label, distinguishing between normal and abnormal
brain tissue. The difficulty in estimating the accurate boundaries between tumor and healthy
tissue in the operating room is reflected in the segmentation labels as well; there is high un-
certainty among neurosurgeons, neuroradiologists, and imaging scientists in delineating these
boundaries.
2.3 The BraTS Data Since its Inception
The mpMRI scans made publicly available through the BraTS initiative, describe T1, T1Gd, T2, and
T2-FLAIR volumes, acquired with different clinical protocols and various scanners from multiple
institutions, mentioned as data contributors in the acknowledgements section. The provided data
are distributed after their harmonization, following standardization pre-processing without affecting
the apparent information in the images. Specifically, the pre-processing routines applied in all the
BraTS mpMRI scans include co-registration to the same anatomical template [6], interpolation to
a uniform isotropic resolution (1mm3), and skull-stripping.
2.3.1 Continuously Growing Publicly Available Dataset The BraTS dataset has evolved over
the years (2012-2018) with a continuously increasing number of patient cases, as well as through
an improvement of the data split used for algorithmic development and evaluation (Table 2).
The first two instances of BraTS (2012-2013) comprised a training and a testing dataset of
35 and 15 mpMRI patient scans, respectively. The results and findings of these two first editions,
were summarized in [1], which to date is the most popular and downloaded paper of the IEEE TMI
journal since its publication, and reflects the interest of the scientific research community in the
BraTS initiative as a publicly available dataset and a community benchmark.
The subsequent three instances of BraTS (2014-2016) received a substantial dataset increase
in two waves and also included longitudinal mpMRI scans. The first wave of increase came in dur-
ing 2014-2015 primarily from contributions of The Cancer Imaging Archive (TCIA) repository [8]
and then Heidelberg University, and the second wave of increase happened in 2016 with contri-
butions from the Center for Biomedical Image Computing and Analytics (CBICA) at the University
of Pennsylvania (UPenn). In addition, stemming from the analysis of the BraTS 2012-2013 re-
sults [1], BraTS 2014-2016 employed ground truth data created by label fusion of top-performing
approaches.
In 2017, thanks to additional contributions to the BraTS dataset, from CBICA@UPenn and the
University of Alabama in Birmingham (UAB), a validation set was included to facilitate algorithm
fine-tuning following a ML paradigm of training, validation, and testing datasets. Notably, in 2017
the number of cases was doubled with respect to the previous year, amounting to 477 cases, which
was further increased in 2018 with 542 cases, thanks to contributions from MD Anderson Cancer
Center in Texas, the Washington University School of Medicine in St. Louis, and the Tata Memorial
Center in India.
2.3.2 Focus Beyond Segmentation BraTS, as indicated by its acronym definition, has primarily
focused on the segmentation to brain tumor sub-regions. However, after its first instances (2012-
2013), its potential clinical relevance became apparent.
BraTS was introduced with secondary tasks, where the results of the brain tumor segmenta-
tion algorithms are used towards promoting further analysis and accelerating discovery. From a
clinical perspective these secondary tasks featured in the BraTS challenge can be crucial towards
fostering the development of algorithms capable of addressing clinical requirements in a more re-
liable manner than the current clinical practice. Specifically, to pinpoint the clinical relevance of the
segmentation task, in the BraTS instances of 2014-2016, longitudinal scans were included in the
publicly available dataset, to evaluate the ability and potential of automated tumor volumetry in as-
sessing disease progression. Along the same lines of research, in the last two instances of BraTS
(2017-2018), clinical data of patient age, overall survival, and resection status were included, to fa-
cilitate the secondary task of predicting patient overall survival via integrative analyses of radiomic
features and ML algorithms.
2.3.3 The Latest BraTS Data The datasets used in BraTS 2017 and 2018 have been updated
(since BraTS 2016), with more routine clinically-acquired 3T mpMRI scans and all the ground
truth labels have been evaluated, and manually-revised when needed, by expert board-certified
neuroradiologists. Ample multi-institutional (n=19) routine clinically-acquired pre-operative mpMRI
scans of GBM/HGG and LGG, with pathologically confirmed diagnosis and available OS, were
provided as the training, validation and testing data.
The data provided since BraTS 2017 differs significantly from the data provided during the
previous BraTS challenges (i.e., 2016 and backwards). Specifically, since BraTS 2017, expert
Table 2: Summarizing the distribution of the BraTS data across the training, validation, and test-
ing sets, since the inception the of BraTS initiative, together with the focused tasks of its BraTS
instance.
Year Total Training Validation Testing Tasks Type of datadata data data data
2012 50 35 N/A 15 Segmentation Pre-operative only
2013 60 35 N/A 25 Segmentation Pre-operative only
2014 238 200 N/A 38 Segmentation LongitudinalDisease progression
2015 253 200 N/A 53 Segmentation LongitudinalDisease progression
2016 391 200 N/A 191 Segmentation LongitudinalDisease progression
2017 477 285 46 146 Segmentation Pre-operative onlySurvival prediction
2018 542 285 66 191 Segmentation Pre-operative onlySurvival prediction
neuroradiologists have radiologically assessed the complete original TCIA glioma collections (i.e.,
TCGA-GBM, n=262 [9] and TCGA-LGG, n=199 [10]) and categorized each scan as pre-operative
or post-operative. Subsequently, all the pre-operative TCIA scans (i.e., 135 GBM [3] and 108 LGG
[4]) were annotated by experts for the various sub-regions and included in the BraTS datasets
[2–4].
2.3.4 Data Availability As one of the main objectives of the BraTS initiative is to provide an
open source repository for continuous development of algorithms, the data of BraTS 2012-2016
has been made available through the Swiss Medical Image Repository (SMIR - www.smir.ch), and
the data of BraTS 2017-2018 through the Image Processing Portal of the CBICA@UPenn (IPP -
ipp.cbica.upenn.edu). Both platforms feature downloading of datasets, as well as the automatic
evaluation of the results submitted by participants.
2.3.5 The Ranking Scheme for the Segmentation Task (BraTS 2017-2018) The ranking scheme
followed during the BraTS 2017 and 2018 comprised the ranking of each team relative to its com-
petitors for each of the testing subjects, for each evaluated region (i.e., AT, TC, WT), and for each
measure (i.e., Dice and Hausdorff (95%)). For example, in BraTS 2018, each team was ranked
for 191 subjects, for 3 regions, and for 2 metrics, which resulted in 1146 individual rankings. The
final ranking score (FRS) for each team was then calculated by firstly averaging across all these
individual rankings for each patient (i.e., Cumulative Rank ), and then averaging these cumulative
ranks across all patients for each participating team. This ranking scheme has also been adopted
in other challenges with satisfactory results, such as the Ischemic Stroke Lesion Segmentation
(ISLES - http://www.isles-challenge.org/) challenge [11,12].
We also conducted further permutation testing, to determine statistical significance of the rel-
ative rankings between each pair of teams. This permutation testing would reflect differences in
performance that exceeded those that might be expected by chance. Specifically, for each team
we started with a list of observed subject-level Cumulative Ranks, i.e., the actual ranking described
above. For each pair of teams, we repeatedly randomly permuted (i.e., 100,000 times) the Cumula-
tive Ranks for each subject. For each permutation, we calculated the difference in the FRS between
this pair of teams. The proportion of times the difference in FRS calculated using randomly per-
muted data exceeded the observed difference in FRS (i.e., using the actual data) indicated the
statistical significance of their relative rankings as a p-value. These values were reported in an
upper triangular matrix.
2.3.6 Prediction of Patient Overall Survival (BraTS 2017-2018) We identified 346 GBM pa-
tients with overall survival (OS), age, and resection status information. 164 of them had undergone
surgery with gross total resection (GTR) status. The distributions of OS of GBM patients across the
training, validation and testing datasets were matched (Table 3). The patients were divided in three
groups of survival comprising long-survivors (who survived more than 15 months), short-survivors
(who survived less than 10 months), and mid-survivors (who survived between 10 and 15 months).
These thresholds were derived after statistical consideration of the survival distributions across the
complete dataset. Specifically, we chose these thresholds based on equal quantiles from the me-
dian OS (approximately 12.5 months) to avoid potential bias towards one of the survival groups
(short- vs long- survivors) and while considering that discrimination of groups should be clinically
meaningful. The median OS of the described cohorts is not significantly different from the me-
dian OS of GBM patients in several randomized Phase III trials, noting that our cohort consists of
unselected patients rather than those eligible for such trials [13,14].
The population of patients with available OS information was randomly and proportionally di-
vided into the training, validation and testing sets. This process formed a) the training set, consist-
ing of 163 cases (59 with GTR), b) the validation set, consisting of 53 cases (28 with GTR), and
c) the testing set, consisting of 130 cases (77 with GTR). Table 3 shows the distribution of patient
cases for the task of the OS prediction.
Participating teams were requested to submit OS prediction results in days for each patient
with GTR. The evaluation system then automatically classified these into short-, intermediate-,
and long-survivors.
2.3.7 Evaluation Framework For consistency purposes both in BraTS 2017 & 2018 challenges,
two reference standards were used for the two tasks of the challenge: 1) manual segmentation
labels of tumor sub-regions, and 2) clinical data of OS.
The introduction of the validation set since BraTS 2017 allows participants to obtain preliminary
results in unseen data, in addition to their cross-validated results on the training data. The ground
truth of the validation data was never provided to the participants. Finally, all participants were pre-
sented with the same test data, for a limited controlled time-window (48h), before the participants
are required to submit their final results for quantitative evaluation and their ranking.
For the segmentation task, and for consistency with the configuration of the previous BraTS
challenges, the ”Dice score” and the ”Hausdorff distance” were used. Expanding upon this evalu-
ation scheme, the metrics of ”Sensitivity” and ”Specificity” were also used, allowing to determine
potential over- or under-segmentations of the tumor sub-regions by participating methods. Since
the BraTS 2012-2013 were subsets of the BraTS 2018 test data, performance comparison on the
2012-2013 data will allow for a direct evaluation against the performances reported in [1].
For the task of survival prediction, two evaluation schemes are considered. First, for ranking the
participating teams, evaluation will be based on the classification of subjects as long-, intermediate-
, and short-survivors. Predictions of the participating teams will be assessed based on classifica-
tion accuracy (i.e. the number of correctly classified patients) with respect to this grouping. Note
that participants are expected to provide predicted survival status only for subjects with resec-
tion status of GTR (i.e., Gross Total Resection). In addition, a pairwise error analysis between the
predicted and actual survival in days was conducted and the results were shared with the partici-
pants, to allow the evaluation of their method for outliers. This analysis was done using the metrics
Table 3: The overall survival distribution of patients across the training, validation, and testing sets
of BraTS 2017 and 2018.
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of Mean-Square Error (MSE), median square error (medianSE), standard deviation of the square
errors (stdSE), and the spearman correlation coefficient (spearmanR).
3 Results
3.1 BraTS 2012-2013
To emphasize the most interesting results of our previously published analyses summarizing BraTS
2012 and BraTS 2013 [1], we focus into two main points (Fig. 4). First, we note that even though
most of the individual automated segmentation methods performed well, they did not outperform
the inter-rater agreement, across expert clinicians, who have been trained for years to identify
regions of infiltration and distinguish them from healthy brain. Secondly, the fusion of segmentation
labels from top-ranked algorithms out-performed all individual methods and was comparable to
inter-rater agreement. More specifically, while we observe that individual automated segmentation
Fig. 4: Summary results of the BraTS 2012-2013. Label fusion (red outline) out-performs all indi-
vidual methods and the inter-rater agreement. Figure adopted from [1].
methods do not necessarily rank equally well in the different tumor segmentation tasks and under
all metrics (i.e., when evaluating WT, TC, and AT segmentation, with respect to Dice score and
Hausdorff distance), we note that the fused segmentation labels do consistently rank first in all
tasks and both metrics. This suggests that ensembles of fused segmentation algorithms may be
the favorable approach when translating tumor segmentation methods into clinical practice.
3.2 BraTS 2017 (Testing Phase)
During the testing phase of the BraTS 2017 challenge, we note participation of 48 independent
teams [15–62]. Specifically, results for the segmentation task were submitted by 47 teams and for
the survival prediction task by 16 teams (1 of which did not participate in the segmentation task).
The ranking of the participating teams depicts a gradual improvement of the ranked approaches
(Fig. 5-6). We note that the variability of the ranked approaches (Fig. 5) does not dramatically
change across any two sequentially ranked teams, indicating no particular dominance of a method
over the other closely ranked methods. In order to assess potential statistically significant per-
formance differences across teams, we also performed a pairwise comparison for significant dif-
ferences based on 100,000 permutations. This allowed us to include a tie in the 3rd rank of the
segmentation task (Table 4). Specifically, the statistical evaluation of the top-ranked teams revealed
that the first team was statistically better from the second (p-value¡0.0003), whereas the second
team was not statistically better than the third (p¿0.1) and the fourth (p¿0.14), but only from the
fifth (p=0.01). This justified the decision of a tie in the third rank.
3.3 BraTS 2018 (Testing Phase)
During the testing phase of the BraTS 2018 challenge, we note participation of 63 independent
teams [63–125]. Specifically, results for the segmentation task were submitted by 61 teams and for
the survival prediction task by 26 teams (2 of which did not participate in the segmentation task).
Fig. 5: BraTS 2017 Ranking of all Participating Teams in Segmentation Task. (smaller values are
higher ranks)
The BraTS 2018 results for the segmentation of the AT (Suppl.Fig. 9) show a very marked
skewness in the distribution of Dice metrics, as seen in the average and median values (crosses
Fig. 6: BraTS 2017 Ranking of all Participating Teams in Survival Task. (larger values are better)
Table 4: Top-ranked participating teams in BraTS 2017 for both the segmentation and the survival
prediction tasks.
Task Rank Team First Author Institution Paper
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1 biomedia1 Konstantinos Kamnitsas Imperial College London, UK [33]
2 UCL-TIG Guotai Wang University College London (UCL), UK [55]
3 (tie) MIC DKFZ Fabian Isensee Division of Medical Image Computing, German
Cancer Research Center (DKFZ), Heidelberg,
Germany
[29]
3 (tie) CMR Tsai-Ling Yang National Taiwan University of Science and Tech-
nology, Taipei, Taiwan
[57]
S
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va
l 1 VisionLab Zeina Shboul Old Dominion University, USA [52]
2 UBERN UCLM Alain Jungo University of Bern, Switzerland [32]
3 xfeng Xue Feng Biomedical Engineering, University of Virginia,
USA
[27]
and vertical lines on each boxplot). These results illustrate the tendency of most methods to per-
form relatively well, in terms of median Dice (Median Dice for top 54/63 teams: [0.74-0.85]), but
also the difference in levels of robustness as the average Dice is affected by increasing number
of outliers in the results (Average Dice of same 54/63 teams: [0.61-0.77]). Segmentation results of
the TC (Suppl.Fig. 10) presents a similar pattern, with the results of the AT, across teams. Simi-
larly with observations from previous BraTS instances [1], the top positions are not systematically
taken by the same teams, reflecting the added value of fusing segmentation labels from different
Table 5: Top-ranked participating teams in BraTS 2018 for both the segmentation and the survival
prediction tasks.
Task Rank Team First Author Institution Paper
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1 NVDLMED Andriy Myronenko NVIDIA, Santa Clara, USA [100]
2 MIC-DKFZ Fabian Isensee Division of Medical Image Computing, German
Cancer Research Center (DKFZ), Heidelberg,
Germany
[86]
3 (tie) SCAN Richard McKinley Support Centre for Advanced Neuroimaging Insel-
spital, Bern University Hospital, Switzerland
[97]
3 (tie) DL 86 81 Chenhong Zhou School of Electronic & Information Engineering,
South China University of Technology, China
[125]
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1 xfeng Xue Feng Biomedical Engineering, University of Virginia,
USA
[75]
2 (tie) LRDE E´lodie Puybareau EPITA Research and Development Laboratory,
France
[104]
2 (tie) SUSTech Li Sun Southern University of Science & Technology,
China
[111]
3 (tie) TRAP Ujjwal Baid Shri Guru Gobind Singhji Institute of Engineering
and Technology, India
[64]
3 (tie) LfB RWTH Leon Weninger Institute of Imaging & Computer Vision, RWTH
Aachen University, Germany
[117]
approaches. In comparison to the AT, segmentation of the TC seems in general to be more robust
(i.e., median inter-quantile range (IQR) for Dice of same 54/63 teams, for TC is 0.16, vs. 0.18 for
the AT). It is worth mentioning though that the Dice metric is more sensitive to error of the AT, due
to its typically much smaller volume. As also noted in previous instances of BraTS, the segmen-
tation of the WT (Suppl.Fig. 11) represents the most robust and accurate segmentation results of
the three evaluated tumor compartments (i.e., AT, TC, WT), with a median Dice coefficient of 0.9
for most of the participating teams.
The 95% Hausdorff distance metric is used to characterize the levels of robustness of the
automated results. Supplementary Figures 12 through 17 show the Hausdorff metric values for the
three evaluated tumor compartments for all teams. Overall, the results for the AT seems to be the
most robust for all three tumor labels (median IQR of 1.9 for the same 54/63 teams), followed by the
results for the WT and that for the TC (IQR of 4.0 and 5.4 for the same 54/63 teams, respectively).
At the patient-wise ranking of the participating teams (Fig. 7) the distribution follows more
closely a gradual improvement of the ranked approaches, similar to results from BraTS 2017.
Worth noting is that the variability of the ranking of approaches at the case level does not dramat-
ically change across teams, indicating no particular dominance of a method over the others. We
also performed a pairwise comparison for significant differences based on 100,000 permutations
that showed the statistically significant performance across teams. Specifically, the statistical eval-
uation of the top-ranked teams revealed that the first team was statistically better from the second
(p-value=0.02), whereas the second team was not statistically better than the third (p=0.06) and
the fourth (p=0.07), but only from the fifth (p=0.01). This justified the decision of a tie in the third
rank.
Results of the survival task are shown in Fig. 8. Overall, the top-5 approaches obtained an
accuracy around 0.6, while the rest of teams obtained an accuracy in the range of [0.15-0.55].
We should clarify that the random choice should be considered the 0.33 since this is a 3-class
classification.
The final top-performing participating teams positioned in ranks 1-3 are shown in Table 5.
Fig. 7: BraTS 2018 Ranking of all Participating Teams in Segmentation Task. (smaller values are
higher ranks)
Fig. 8: BraTS 2018 Ranking of all Participating Teams in Survival Task. (larger values are better)
4 Discussion
4.1 Performance of Automated Segmentation Methods
While the accuracy of individual automated segmentation methods has improved, we note that their
level of robustness is still inferior to expert performance, i.e., inter-rater agreement. This robustness
is expected to be continuously improving as the training set increases in size, in virtue of captur-
ing and describing more diverse patient populations, along with improved training schemes and
ML architectures. Beyond these speculative expectations, the results of our quantitative analyses
support that the fusion of segmentation labels from various individual automated methods shows
robustness superior to the ground truth inter-rater agreement (provided by clinical experts), in
terms of both accuracy and consistency across subjects. However, proposed strategies to ensem-
ble several models correspond to one practical way to reduce outliers and improve the precision of
automated segmentation systems, by means of consensus segmentation across different models.
We consider future research essential, in order to improve the robustness of individual approaches
by increasing the ability of segmentation systems to handle confounding effects typically seen in
images acquired using routine clinical workflows. Related to BraTS such effects include, but are not
limited to, a) the presence of blood products, b) ”air-pockets”/resection cavities in post-operative
scans, c) better differentiation (or handling) of non-GBM entities, and d) improved performance
for low-grade gliomas, featuring diffuse boundaries, especially while considering cases without AT
sub-regions, and e) high sensitivity to effectively detect and assess their slow progression.
4.2 BraTS Ranking Schema
The BraTS challenge recently adopted a case-wise ranking schema, which enables a more clinically-
relevant evaluation of participating teams, as it considers the complexity of patient cases that can
vary significantly. Furthermore, the additional featured evaluation of statistical significance of differ-
ences across algorithmic results, also enables the evaluation of results across different instances
of the BraTS challenge, which in turns enables a thorough analysis of the improvement attained
over the last seven years of the BraTS initiative.
4.3 Beyond Segmentation
Importantly, two more clinically-relevant tasks/sub-challenges have been complementarily added
in the BraTS initiative during these past seven years, aiming at emphasizing the clinical relevance
of the brain tumor segmentation task. Both these clinically-relevant tasks promote the natural uti-
lization of segmentation labels to answer clinical questions, address clinical requirements, and
potentially support the clinical decision-making process. The ultimate goal of these additions was
to evaluate the potential usability and pave the way of automated segmentation methods towards
their translation to routine clinical practice.
4.3.1 Assessment of Disease Progression The inclusion of longitudinal (i.e., follow up) mpMRI
scans took place during the BraTS 2014-2016 instances. In clinical practice, assessment of dis-
ease progression is to date performed through the Response Evaluation Criteria In Solid Tu-
mours (RECIST) [126–129] and the Response Assessment in Neuro-Oncology (RANO) criteria
[130], whose quantitative component is based on the relative change of tumor size (i.e., percentile
changes) measured by the longest two axes of the assessed tumor. In this regard, we postulate that
automated algorithms performing brain tumor volumetric segmentation (i.e., in three dimensions)
should yield reliable comparable (if not better) estimates of volumetric tumor changes.
4.3.2 Prediction of Overall Survival The inclusion of the OS prediction task took place dur-
ing the BraTS 2017-2018 instances and has highlighted (or rather confirmed) the difficulties of
Deep Learning (DL) approaches to handle small training sets, and the superiority of traditional ML
approaches. While this finding clearly calls for larger training sets, it also identifies the need for
potential synergies between DL and traditional ML approaches as we transition to larger training
sets in the future, which can include more non-uniformly distributed clinical and/or molecular infor-
mation. In other words, there is a need to develop advanced ML approaches able to handle the
large existing heterogeneity of the patient-specific information available in the clinics, e.g., radio-
genomics [131–138], RIS reports.
4.4 Future Directions for the BraTS Initiative
The current trend over the years of the previous BraTS instances highlights (or rather confirms)
a) the superiority of DL over traditional ML approaches in the segmentation task (and particularly
in terms of Dice), and, in contrast, b) the struggle of DL and the superiority of traditional ML ap-
proaches, assessing more clinically-relevant problems, such as the prediction of clinical outcome
(i.e., overall survival), where smaller training sets are typically available and need to be handled.
Concentrating on the segmentation task, in terms of algorithmic design, the current general
consensus seems to point in the direction of tackling the problem in a hierarchical/cascaded way,
by first distinguishing between normal and abnormal/tumorous tissue, and then proceeding with the
segmentation of the tumor sub-regions. Alternative research directions include the enhancement
of the flexibility of DL systems that might lack a given set of input images [139], as a transition
measure towards worldwide adoption of the standardization initiatives for GBM imaging [140].
There are many clinical endpoints where the BraTS initiative can have a potential impact and
these include, but not limited to: a) training systems for neuroradiology trainees, b) differential di-
agnosis (e.g., metastases differentiation, disease progression assessment, radio-phenotyping), c)
prognosis (e.g., prediction of overall survival, drug-response prediction), d) radiation therapy plan-
ning. However, for any of these to be potentially considered wider application of the developed
methods needs to take place, which is why we created the BraTS algorithmic repository, and a
closer collaboration with the clinical expertise is fundamental to tailor the design of the BraTS chal-
lenges towards an effective exploitation and translation of research findings into clinical practice.
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6 Supplementary Material
6.1 BraTS 2018 Detailed Evaluation
Fig. 9: BraTS 2018 summarizing results (Dice) for the segmentation of the active tumor compart-
ment.
Fig. 10: BraTS 2018 summarizing results (Dice) for the segmentation of the tumor core compart-
ment.
Fig. 11: BraTS 2018 summarizing results (Dice) for the segmentation of the whole tumor compart-
ment.
Fig. 12: BraTS 2018 summarizing results (Hausdorff) for the segmentation of the active tumor
compartment.
Fig. 13: BraTS 2018 summarizing results (Hausdorff) for the segmentation of the active tumor
compartment, with cutoff values for visualization purposes.
Fig. 14: BraTS 2018 summarizing results (Hausdorff) for the segmentation of the tumor core com-
partment.
Fig. 15: BraTS 2018 summarizing results (Hausdorff) for the segmentation of the tumor core com-
partment, with cutoff values for visualization purposes.
Fig. 16: BraTS 2018 summarizing results (Hausdorff) for the segmentation of the whole tumor
compartment.
Fig. 17: BraTS 2018 summarizing results (Hausdorff) for the segmentation of the whole tumor
compartment, with cutoff values for visualization purposes.
6.2 BraTS 2017 Detailed Evaluation
Fig. 18: BraTS 2017 summarizing results (Dice) for the segmentation of the active tumor compart-
ment.
Fig. 19: BraTS 2017 summarizing results (Dice) for the segmentation of the tumor core compart-
ment.
Fig. 20: BraTS 2017 summarizing results (Dice) for the segmentation of the whole tumor compart-
ment.
Fig. 21: BraTS 2017 summarizing results (Hausdorff) for the segmentation of the active tumor
compartment.
Fig. 22: BraTS 2017 summarizing results (Hausdorff) for the segmentation of the active tumor
compartment, with cutoff values for visualization purposes.
Fig. 23: BraTS 2017 summarizing results (Hausdorff) for the segmentation of the tumor core com-
partment.
Fig. 24: BraTS 2017 summarizing results (Hausdorff) for the segmentation of the tumor core com-
partment, with cutoff values for visualization purposes.
Fig. 25: BraTS 2017 summarizing results (Hausdorff) for the segmentation of the whole tumor
compartment.
Fig. 26: BraTS 2017 summarizing results (Hausdorff) for the segmentation of the whole tumor
compartment, with cutoff values for visualization purposes.
